SeaSpine Holdings (SPNE) Trades at $10.03 After Triangle; Abbvie (ABBV) Shorts Decreased By 7.14%

December 28, 2017 - By John Hoffman

Abbvie Incorporated (NYSE:ABBV) had a decrease of 7.14% in short interest. ABBV’s SI was 14.07 million shares in December as released by FINRA. Its down 7.14% from 15.15 million shares previously. With 4.10 million avg volume, 3 days are for Abbvie Incorporated (NYSE:ABBV)’s short sellers to cover ABBV’s short positions. The stock increased 0.35% or $0.34 during the last trading session, reaching $98.09. About 1.93M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since December 28, 2016 and is uptrending. It has underperformed by 6.07% the S&P500.

SeaSpine Holdings Corporation (SPNE) formed triangle with $10.73 target or 7.00% above today’s $10.03 share price. SeaSpine Holdings Corporation (SPNE) has $134.69 million valuation. The stock increased 0.20% or $0.02 during the last trading session, reaching $10.03. About 10,304 shares traded. SeaSpine Holdings Corporation (NASDAQ:SPNE) has risen 6.47% since December 28, 2016 and is uptrending. It has underperformed by 10.23% the S&P500.

Analysts await SeaSpine Holdings Corporation (NASDAQ:SPNE) to report earnings on March, 1. They expect $-0.54 earnings per share, up 37.93% or $0.33 from last year’s $-0.87 per share. After $-0.58 actual earnings per share reported by SeaSpine Holdings Corporation for the previous quarter, Wall Street now forecasts -6.90% EPS growth.

Among 3 analysts covering SeaSpine Hldgs (NASDAQ:SPNE), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SeaSpine Hldgs had 5 analyst reports since June 21, 2017 according to SRatingsIntel. BTIG Research maintained SeaSpine Holdings Corporation (NASDAQ:SPNE) on Tuesday, July 11 with “Buy” rating. Piper Jaffray maintained the shares of SPNE in report on Friday, August 18 with “Buy” rating. As per Thursday, September 28, the company rating was maintained by Piper Jaffray.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $156.59 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 23.83 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

Since July 31, 2017, it had 0 insider buys, and 8 insider sales for $45.57 million activity. 87,040 shares valued at $8.57 million were sold by RICHMOND TIMOTHY J. on Monday, December 18. $21,127 worth of AbbVie Inc. (NYSE:ABBV) was sold by Gosebruch Henry O on Monday, July 31. GONZALEZ RICHARD A sold $6.24 million worth of AbbVie Inc. (NYSE:ABBV) on Thursday, August 3. Michael Robert A. had sold 6,699 shares worth $589,512. On Monday, September 11 SALEKI-GERHARDT AZITA sold $705,655 worth of AbbVie Inc. (NYSE:ABBV) or 8,300 shares. $14.07M worth of AbbVie Inc. (NYSE:ABBV) shares were sold by Schumacher Laura J.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Abbvie Inc had 69 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Credit Suisse with “Hold” on Thursday, July 20. Citigroup upgraded AbbVie Inc. (NYSE:ABBV) on Tuesday, February 23 to “Buy” rating. The rating was maintained by BMO Capital Markets on Sunday, July 30 with “Hold”. Cowen & Co maintained it with “Buy” rating and $105.0 target in Monday, November 20 report. The stock of AbbVie Inc. (NYSE:ABBV) has “Hold” rating given on Wednesday, April 19 by BMO Capital Markets. As per Friday, July 14, the company rating was maintained by Jefferies. The rating was upgraded by Cowen & Co to “Outperform” on Wednesday, October 11. The firm earned “Buy” rating on Friday, March 10 by Goldman Sachs. The company was maintained on Wednesday, June 7 by BMO Capital Markets. Societe Generale initiated the shares of ABBV in report on Wednesday, April 6 with “Sell” rating.

Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It is negative, as 55 investors sold AbbVie Inc. shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Laurel Grove Lc reported 1.4% in AbbVie Inc. (NYSE:ABBV). Barbara Oil has invested 1.23% in AbbVie Inc. (NYSE:ABBV). State Common Retirement Fund holds 4.15M shares. Utah Retirement invested 0.58% of its portfolio in AbbVie Inc. (NYSE:ABBV). Moody Commercial Bank Tru Division has 11,508 shares. Westwood Holdings Grp stated it has 9,836 shares or 0.01% of all its holdings. Hillsdale Mngmt reported 5,560 shares or 0.08% of all its holdings. Sky Gru Limited Liability Corporation invested 0.46% in AbbVie Inc. (NYSE:ABBV). Palouse Capital reported 67,410 shares stake. Peapack Gladstone Fincl Corporation invested 0.83% of its portfolio in AbbVie Inc. (NYSE:ABBV). Moreover, Schafer Cullen Capital Inc has 0.07% invested in AbbVie Inc. (NYSE:ABBV) for 66,690 shares. Citadel Advsr Ltd Com holds 0.01% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 165,888 shares. Lsv Asset Management stated it has 6.84M shares or 1% of all its holdings. 2.15 million were reported by Nordea Inv Mgmt Ab. Supplemental Annuity Collective Trust Of Nj reported 15,000 shares.